| Clinical efficacy of drug-coated device in treatment of ostial vertebral artery stenosis |
| Received:August 27, 2021 Revised:December 22, 2021 Click here to download the full text |
| Citation of this paper:WANG Yong-gang,SHI Zhen-yu,GUO Da-qiao,TANG Xiao,SI Yi,GUO Bao-lei.Clinical efficacy of drug-coated device in treatment of ostial vertebral artery stenosis[J].Chinese Journal of Clinical Medicine,2022,29(2):147-152 |
| Hits: 1029 |
| Download times: 347 |
| Author Name | Affiliation | E-mail | | WANG Yong-gang | Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | SHI Zhen-yu | Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China | maxshizhenyu@163.com | | GUO Da-qiao | Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | TANG Xiao | Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | SI Yi | Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | GUO Bao-lei | Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China | |
|
| Abstract:Objective To evaluate the safety and effectiveness of drug-coated devices for patients with ostial vertebral artery stenosis (OVAS). Methods Clinical data of 18 consecutive OVAS patients treated with drug-coated devices admitted to the Department of Vascular Surgery of Zhongshan Hospital, Fudan University from January 2018 to December 2020 were retrospectively analyzed. All patients underwent preoperative computed tomography angiography, magnetic resonance angiography and/or carotid ultrasound to clarify the degree of stenosis, and confirmed by digital subtraction angiography if necessary. Surgical methods for new OVAS lesion were: drug-coated balloon(DCB), DCB＋bare metal stent, drug-eluting stent(DES); for restenotic OVAS lesion were: DCB, DES. The perioperative clinical success rate, technical success rate, incidence of adverse events were observed. Regular postoperative follow-up was performed to observe the vascular patency rate, the incidence of adverse events and the rate of secondary interventions. Results Among 18 patients, 16 had new lesions and 2 had restenotic lesions. There were 12 males and 6 females; ages ranged from 54 to 84 years old, with a mean age of (67.5±7.8) years old. 16 patients with new OVAS: 6 patients with DCB, 8 patients with DES, and 2 patients with DCB＋bare metal stent; 2 patients with restenosis OVAS: 1 patient with DES and 1 patient with DCB. One patient had unrelieved vertigo symptoms and one patient had a cerebellar stroke during the perioperative period. The technical success rate was 94.4% (17/18), the clinical success rate was 88.9% (16/18), and the incidence of perioperative adverse events was 5.6% (1/18). The follow-up time was 3-38 months with a mean follow-up time of (15.4±10.9) months. One patient with vertigo symptoms improved during the follow-up period without any treatment, and one patient with stroke improved after symptomatic support treatment without any treatment. During follow-up, restenosis occurred in one new lesion patient in 3 months post-treatment. The vascular patency rate was 94.4% (17/18), the incidence of adverse events was 5.6% (1/18), the rate of secondary intervention was 0%. Conclusion Drug-coated device is safe and effective for the treatment of OVAS patients with low restenosis rate. |
| keywords:ostial vertebral artery stenosis endovascular therapy bare metal stent drug-coated devices |
| HTML View Full Text View/Add Comment Download reader |
|
|
|